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Introduction 
The improved understanding of the intersection of HIV, 
aging and health is an urgent issue due to the increasing number 
of people aging with HIV as the synergistic result of two 
concurrent phenomena: people living with HIV (PLWH) live 
longer and more people catch HIV at an older age (1, 2). 
The former fact results from the increased life expectancy 
guaranteed by antiretroviral therapy (ART); the latter from a 
changed perception of sexual risk in older people (3, 4).
The aging epidemic of PLWH arouses potential concern due 
to physical, neurocognitive and psychological issues that can 
accompany both aging and HIV infection (5).
Aging with HIV is often linked to non-infectious 
comorbidities (NICM), including cardiovascular disease 
(CVD), hypertension (HTN), dyslipidaemia (DLP), type 2 
diabetes mellitus (T2DM), chronic kidney disease (CKD), 
osteopenia/osteoporosis (O/O), and non-AIDS cancers (NAC). 
These heterogeneous NICM share age and HIV infection as 
independent risk factors and tend to aggregate into complex 
multi-morbidity (MM) patterns (6, 7).
The current literature focusing on HIV in older people 
concentrates on studies comparing older with younger HIV-
positive individuals, or else comparing HIV-positive to HIV-
negative older individuals (8, 9). Such comparative studies have 
begun to highlight the diversity of individuals aging with HIV, 
in terms of behavioural factors, social vulnerability, and ethno-
racial disparities, which might contribute to different patterns of 
aging (1).
In a published study including ART-experienced patients, 
we showed that host factors and duration of HIV infection 
were associated with an increased risk of MM compared to the 
general population (10).
Comparing PLWH with diverse age but similar exposure to 
HIV might help us to better depict the relationship between age 
and HIV. We hypothesized that age of HIV acquisition impacts 
on the prevalence of NICM.
The objective of the study was to assess the prevalence 
of and risk factors for individual comorbidities and multi-
morbidity in PLWH with similar duration of HIV infection, 
notwithstanding a 25-year difference at the time of HIV 
acquisition. 
In detail, we compared PLWH for 25 years who acquired 
HIV infection at birth, at 25 and at 50 years of age with age and 
sex matched community dwelling people aged 25, 50 and 75 
years.
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This is a match-control study, including ART–experienced 
patients from: 
1. Modena HIV Metabolic Clinic (MHMC), a tertiary 
level HIV clinic opened in 2003. Collecting over 4,500 HIV 
patients referred from all over Italy, MHMC provides annual 
multidisciplinary evaluation to PLWH, including assessment 
for metabolic alterations, NICM and MM.
2. Romanian National Institute for Infectious Diseases 
“Prof. Dr. Matei Bals” (Romanian HIV Clinic, RHC), which 
was established in 1990 and gathered over 1,094 cases of 
paediatric HIV.
Patients selected from these two centres were included on 
a number of conditions: first of all, if they had been living 
with HIV for 25 years and within the three pre-specified age 
groups; secondly, if they were currently undergoing ART with 
undetectable plasma HIV RNA viral load; finally, if they had 
been screened for NICM.
These patients were age and sex matched with individuals 
from the general population selected from Consorzio 
interuniversitario per il calcolo automatico (CINECA ARNO) 
observatory, in Italy.
3. The CINECA ARNO Observatory is an on-line, multi-
centre observational database in which population-based data 
are collected and epidemiological methods are used to combine 
and aggregate large volumes of health and healthcare-related 
files for each participant (11). These data include primary 
care provider-generated medication prescriptions, inpatient 
hospital records and discharge, diagnostic laboratory tests and 
radiographic examinations. From this administrative cohort, 
NICM diagnoses are provided by International Classification 
of Diseases, Tenth Revision. CINECA ARNO does not collect 
lifestyle, anthropometric and metabolic data.
Data were collected in the fourth quarter of 2016.
The following age group strata were identified:
- Group “Young” was selected from RHC. It comprises patients 
prenatally infected and assessed at the age of 25-30 years;  
- Group “Old” was selected from MHMC. It comprises patients 
infected at the age of 25 years and assessed at the age of 
50-55 years;  
- Group “Geriatric” was selected from MHMC. It comprises 
patients diagnosed at the age of 50 years and assessed at the 
age of 75-80 years;  
- Controls were selected from the CINECA ARNO 
observational database and matched according to age, sex, 
and race.
The matching could not compensate for relevant socio-
demographic differences between MHMC and RHC, while 
both of them were compared with general Italian population 
collected by CINECA ARNO.
HIV variables included current and nadir CD4 cell counts, 
current and cumulative exposure to ART drug classes. 
Study outcomes comprised the following NICM diagnosed 
according to guideline-based criteria: CVD, HTN, T2DM, 
lipodystrophy (12). 
MM was defined as the concurrent presence of ≥ 3 NICM 
(13, 14).
Statistical analyses
Comparisons between groups were performed using x2 test 
for categorical variables with Bonferroni adjusted post-hoc 
analyses (significant level set at p<0.017) and t-test or Mann-
Whitney U-test for normally and non-normally distributed 
continuous variables, respectively.
A logistic regression analyses was performed to identify 
the probability of MM comparing both “Old” and “Geriatric” 
groups to “Young” used as a reference, and by comparing HIV 
patients to the general population after correction for sex.
A 1:5 matching of HIV patients with CINECA-ARNO 
records allowed us to obtain medium Cohen’s effect size as 0.6, 
enabling us to estimate a power size of 0.87.
Statistical analyses were performed with R software version 
3.4.2 for Linux.
Results
A total number of 131 HIV positive patients (the “Young” 
group involved 32 patients, while “Old” and “Geriatric” 
contained 77 and 22 patients respectively) and 655 controls 
(the “Young” group comprised 160 patients, while “Old” and 
“Geriatric” contained 385 and 110 patients respectively) were 
included. 
Univariate analysis was conducted to describe demographic 
and anthropometric characteristics, HIV variables, cumulative 
Figure 1
Prevalence of comorbidities and MM in the study groups compared to the general population
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Table 1
Demographic and HIV-related variables in HIV study groups
Total Group A (Young) Group B (Old) Group C (Geriatric) p-value
Number (%) 131(100%) 32 (24.43%) 77 (58.78%) 22 (16.79%)  
Demographic and anthropometric characteristics  
Female, n (%) 45 (34.35%) 13 (40.62%) 29 (37.66%) 3 (13.64%) 0.08
BMI, kg/m2, mean (± SD) 23.84 (3.89) 23.58 (3.96) 23.49 (4) 25.34 (3.15) 0.14
Smoker, n (%) 39 (31.71%) 5 (16.67%) 33 (46.48%) 1 (4.55%) <0.01
Alcohol abuse, n (%) 48 (39.67%) 4 (14.29%) 33 (46.48%) 11 (50%) 0.01
IVDU, n (%) 44 (35.2%) 0 (0%) 44 (57.14%) 0 (0%) <0.01
HBV, n (%) 13 (12.5%) 8 (33.33%) 5 (7.94%) 0 (0%) <0.01
HCV, n (%) 42 (40.38%) 1 (4.17%) 40 (63.49%) 1 (5.88%) <0.01
HIV variables
AIDS diagnosis, n (%) 42 (38.18%) 17 (85%) 18 (26.47%) 7 (31.82%) <0.01
CD4 nadir, c/µL median (IQR) 194 (100-285) NA 186 (95-277) 233 (132-368) 0.31
Current CD4, c/µL median (IQR) 580 (394.25-705.75) 621 (370-779) 570 (398-689) 611.5 (515.25-727.75) 0.61
CD4/CD8 ratio, mean (± SD) 0.83 (0.48) NA 0.81 (0.49) 0.96 (0.43) 0.1
ART (cumulative exposure)
NRTI, months, median (IQR) 133 (82.75-185.5) 172.5 (121.5-222.5) 119 (59.25-181.25) 129 (99.25-167.75) <0.01
PI, months, median (IQR) 80.5 (37-143.25) 154.5 (69.25-204.25) 72 (34-120) 47 (23.91) <0.01
NNRTI, months, median (IQR) 46.5 (16.5-95.75) 42 (16.5-98.5) 46 (16-94) 73.5 (33.75-105.5) 0.59
INSTI, months, median (IQR) 32 (17-51.5) 43 (27.75-63.75) 22 (14-50) 19 (14.25-25.25) 0.23
Biochemical parameters 
Hemoglobin, g/dL, mean (± SD) 14.42 (1.81) 14.35 (1.69) 14.33 (1.94) 14.84 (1.58) 0.45
Platelets, 109/L, mean (± SD) 191.13 (59.94) 207.81 (51.08) 181.82 (66.71) 190.94 (46.62) 0.15
WBC, 1012/L, (± SD) 4337.48 (3140.39) 6344.69 (1567.48) 3679 (3281.11) 2805.76 (3178.12) <0.01
Creatinine, mg/dL, mean (± SD) 0.87 (0.24) 0.82 (0.2) 0.87 (0.26) 0.94 (0.21) 0.06
Albumin g/dL, mean (± SD) 5.7 (8.3) 3.27 (3.29) 4.45 (0.42) 4.56 (0.29) 0.31
GOT, U/L, mean (± SD) 36.17 (25.39) 28.21 (10.82) 40.86 (26.24) 31.73 (32.92) 0.02
GPT, U/L, mean (± SD) 43.31 (37.23) 40.03 (44.64) 47.33 (35.33) 35.32 (30.66) 0.2
Glucose, mg/dL, mean (± SD) 98.99 (20.32) 89.52 (9.55) 97.61 (18.21) 115.86 (26.82) <0.01
Cholesterol, mg/dL, mean (± SD) 192.96 (41.97) 192.45 (44.8) 193.5 (41.61) 191.77 (42.2) 0.94
Triglycerides, mg/dL, mean (± SD) 161.79 (87.14) 149.95 (88.24) 155.3 (85.05) 193.73 (89.27) 0.06
HbA1C, %, median (IQR) 5.5 (5.2-6.2) NA 5.4 (5.0-5.7) 6.15 (5.57-7.52) 0.005
NICM (study outcomes)
CKD, n (%) 12 (10.17%) 5 (26.32%) 2 (2.6%) 5 (22.73%) <0.01
CVD, n (%) 9 (7.56%) 3 (15%) 2 (2.6%) 4 (18.18%) 0.02
Hypertension, n (%) 38 (30.65%) 4 (16%) 18 (23.38%) 16 (72.73%) <0.01
Lipodystrophy, n (%) 87 (69.6%) 20 (76.92%) 46 (59.74%) 21 (95.45%) <0.01
Diabetes, n (%) 18 (14.29%) 0 (0%) 5 (6.49%) 13 (59.09%) <0.01
Abbreviations: SD - standard deviation; BMI - body mass index; HIV – human immunodeficiency virus; IQR - interquartile range; IVDU - intravenous drug user; 
HBV – hepatitis B virus; HCV – hepatitis C virus; NRTI - nucleoside reverse transcriptase inhibitor; NNRTI – non-nucleoside reverse transcriptase inhibitor; PI 
– protease inhibitor; INSTI - integrase strand transfer inhibitors; WBC - white blood cell; GOT -glutamic oxaloacetic transaminase;  GPT - glutamate-pyruvate 
transaminase; HTN – hypertension; CVD - cardiovascular disease; CKD - chronic kidney disease
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exposure to ART, biochemical parameters and study outcomes 
in HIV positive groups. With regard to comorbidities, all NICM 
were more prevalent in the “Geriatric” group (table 1). 
The comparison between HIV groups and controls is 
depicted in Figure 1, which shows that the prevalence of NICM 
is higher in PLWH.
A multivariable linear regression model was built to identify 
predictors of MM in all examined groups, using the “Young” 
as reference. HIV serostatus was the highest risk factor for 
MM (OR=47.75, IQR 14.78-154.25, p<0.01). Higher risk for 
MM was displayed in “Geriatric” vs “Young” (OR=30.32, IQR 
5.89-155.98, p<0.01), but not comparing “Young” vs “Old” 
(OR=0.81, IQR 0.14-4.65, p=0.817) and the female gender 
(OR=0.68, IQR 0.18-2.53, p=0.561). 
Discussion
This study depicted NICM and MM in PLWH over 25 years. 
As expected, the prevalence of these conditions was much 
higher in HIV-positive patients, when compared to CINECA 
records. 
The high burden of MM affecting PLWH was shown for 
the first time seven years ago at MHMC (6), and it has been 
reproduced in several other HIV cohorts around the globe since 
then (7). At the time, it was observed that NICM and MM 
were age-related conditions (15). This finding ignited a long-
standing debate regarding accentuated or accelerated aging in 
PLWH. More importantly, it introduced the idea that aging 
in HIV is not simply the effect of anagraphical age. We have 
previously demonstrated that HIV duration is more important 
than anagraphical age for the risk of NICM and MM (10). 
In the present study, we wanted to show that regardless 
of the same, long duration of HIV (25 years), age of HIV 
acquisition impacts on age-related conditions. Apparently, 
our data suggest a “U-curve” phenomenon in which HIV 
acquisition at birth entailed a higher risk for NICM and MM 
than in people who acquired HIV as young adults (25-30 years 
old). Patients who acquired HIV at the age of 50 years or more 
displayed the highest prevalence of NICM (except CKD) and 
MM. This age category was observed to be an independent risk 
factor for MM, after correction for anagraphical age. On the 
contrary, age of HIV acquisition did not affect immunological 
parameters, underlining the high probability of obtaining 
virologic success in a population reaching undetectable HIV 
viral load.
This study contributes to the understanding that HIV is 
an “age modulator”, that is a chronic health condition in 
which not only duration but also age of acquisition modulate 
the biological age of PLWH. The heightened risk for MM 
observed in PLWH, when compared to the general population, 
is therefore the result of three time variables: anagraphical age, 
HIV duration and age of HIV acquisition.
This study also described three age groups which differed for 
multiple demographic, HIV and clinical characteristics.
The “Young” belonged to a unique epidemiology setting 
in which lower socio-economic status and healthcare access 
difficulties, with limited screening and preventive strategies, 
may have contributed to the disease burden of the “Young” 
group (16).
The “Old” were representative of the “first wave” of HIV 
epidemic in Italy. They were more likely to have acquired HIV 
with intravenous drug use and as expected, they were more 
likely to be smokers and heavy drinkers (17).
The “Geriatric” are an emerging population. Over the past 
fifteen years, a significant increase in new HIV/AIDS diagnoses 
has been observed in the elderly population (18). This new 
epidemiological shift has been attributed to a longer sex life, 
lifestyle and changes in sexual behaviour, poor sexual health 
education and misconceptions about absence of sexually 
transmitted disease in later life. In this population, NICM may 
have been present before HIV acquisition (19, 20). In this 
chronological-age vulnerable population, HIV per se and ART 
may represent an additional risk factor for NICM and MM. 
In the European epidemiological context, where an 
increasing number of patients acquire HIV at an older age (2), 
dedicated programs for HIV testing in elderly individuals at 
risk for HIV and routine screening for NICM in HIV elderly 
patients should be reinforced. The fact that the “Geriatric” was 
the most vulnerable group underlines the need of a “geriatric 
HIV care” in the setting of the HIV epidemic. 
Putting this study in the context of contemporary HIV care 
with immediate access and less toxic ART may hopefully 
reduce the burden of NICM and MM in future years. In our 
study, cumulative exposure to “older” drug regimen including 
NRTI and PI/r differed between groups, while the newer 
NNRTI and INSTI regimens were similar. 
This study has relevant limitations, some of which 
inherent in the cross-sectional nature of the study. The major 
limitation lies in the non-obvious reproducibility of these 
results, particularly with regard to the “Young” group. The 
collaboration between MCMC and RHC was necessary in order 
to provide an age group rarely represented in Italy. Italy and 
Romania have a different healthcare system. Moreover, it is 
still difficult to have routine assessments for multiple NICM 
in perinatally infected patients. Additionally, evaluation of the 
NICM in this population differs from the standard assessment 
in adults. The burden of NICM identified in this study suggests 
that routine screening for NICM is a necessary process in the 
care of PLWH.
The small sample size was also a limitation of this study, 
related to both the lack of data on NICM in the “Young” from 
the RHC, and the small number of “Geriatric” from MHMC. 
The small sample size may have been responsible for the 
absence of any patients with cancer. 
In conclusion, these data suggest that age at acquisition of 
HIV infection should be considered as a risk factor for NICM 
and MM.
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